Rucaza 300mg Tablet

Rucaza 300mg tablet is a prescription based medication. It is used as the first line therapy in treatment of ovarian cancer and prostate cancer. Its active ingredient is Rucaparib which belongs to the drug class of PARP (poly ADP ribose polymerase) inhibitors. It works by preventing cancer cells from repairing their DNA, leading to cell death.

The medication is used to slow or stop cancer progression and help improve disease control in eligible patients. It is recommended to consult the doctor regarding the appropriate dosage and duration of the treatment or manage possible side effects before starting the medication.​

• Ovarian cancer and prostate cancer​
  

Some of the medications show various side effects, patient also experiencing side effects while using Rucaza tablet. Discuss the doctor if any of the symptoms persist or worsen.

• Nausea, vomiting
• Changes in the blood count
• Shortness of breath
• Tiredness
• Rash
• Constipation
• Decrease in appetite
• Diarrhea, indigestion
• Severe anemia
• Hypersensitivity reactions
• Sepsis (blood infection)
• Pneumonia​

• Rucaza 300mg tablet should be taken with or without food but at the fixed time everyday to enhance the effectiveness of the treatment. Never skip or stop taking the medication without consultation with a healthcare provider as the medicine can show the side effects or reduce treatment effectiveness if not taken as prescribed.
• Do not double up the dose on the missed one in order to avoid complications during the treatment.
  ​

• Rucaza 300mg tablet contains PARP inhibitor used in prostate and ovarian cancer that blocks the PARP enzyme involved ion DNA repair. Inhibition of PARP causes accumulation DNA damage in cancer cells.
• Tumor cells with BRCA mutation cannot repair the damage and hence in that way It slow or stop the progression of cancer cells in the body.
  
  

• Syed, Y. Y. (2017). Rucaparib: first global approval. Drugs, 77(5), 585-592. https://pubmed.ncbi.nlm.nih.gov/28247266/
• Shirley, M. (2019). Rucaparib: a review in ovarian cancer. Targeted Oncology, 14(2), 237-246. https://pubmed.ncbi.nlm.nih.gov/30830551/
• Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., ... & Bryce, A. H. (2023). Rucaparib or physician’s choice in metastatic prostate cancer. New England Journal of Medicine, 388(8), 719-732. https://pubmed.ncbi.nlm.nih.gov/36795891/
• Balasubramaniam, S., Beaver, J. A., Horton, S., Fernandes, L. L., Tang, S., Horne, H. N., ... & Pazdur, R. (2017). FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation–associated advanced ovarian cancer. Clinical Cancer Research, 23(23), 7165-7170. https://pubmed.ncbi.nlm.nih.gov/28751443/
• Liao, M., Beltman, J., Giordano, H., Harding, T. C., Maloney, L., Simmons, A. D., & Xiao, J. J. (2022). Clinical pharmacokinetics and pharmacodynamics of rucaparib. Clinical Pharmacokinetics, 61(11), 1477-1493. https://pubmed.ncbi.nlm.nih.gov/36107395/